Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Metabolic Disease Drugs Market Insights, Forecast to 2030

Global Metabolic Disease Drugs Market Insights, Forecast to 2030

Industry: Pharma & Healthcare

Published Date: 2024-04-12

Pages: 108 Pages

Report ld: 2920558

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Metabolic Disease Drugs Market Size(US$)

CAGR 2024-2030

10.1%

Market Size,2030

USD 160,970

Million

Market Snapshot

Market Size in 2024 (Value)

US$ 90,370 million

Market Forecast in 2030(Value)

US$ 160,970 million

CAGR

10.1%

Years Considered

2019-2030

Base Year

2024

Forecast Period

2024-2030

Source: Secondary research, interviews with experts, and QYResearch analysis

Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.

Market Analysis and Insights: Global Metabolic Disease Drugs Market

The global Metabolic Disease Drugs market is projected to grow from US$ 90370 million in 2024 to US$ 160970 million by 2030, at a Compound Annual Growth Rate (CAGR) of 10.1% during the forecast period.

The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.

Report Covers:

This report presents an overview of global market for Metabolic Disease Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Metabolic Disease Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Metabolic Disease Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metabolic Disease Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Metabolic Disease Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Metabolic Disease Drugs revenue, projected growth trends, production technology, application and end-user industry.

MARKET SEGMENTATION

By Company

Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other

Segment by Application

Hospital Pharmacy
Retail Pharmacy

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Metabolic Disease Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Glycogen Metabolism Disease Drug

1.2.3 Lipid Metabolism Disease Drug

1.2.4 Amino Acid Metabolism Drug

1.2.5 Other

1.3 Market by Application

1.3.1 Global Metabolic Disease Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Metabolic Disease Drugs Market Perspective (2019-2030)

2.2 Global Metabolic Disease Drugs Growth Trends by Region

2.2.1 Metabolic Disease Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Metabolic Disease Drugs Historic Market Size by Region (2019-2024)

2.2.3 Metabolic Disease Drugs Forecasted Market Size by Region (2025-2030)

2.3 Metabolic Disease Drugs Market Dynamics

2.3.1 Metabolic Disease Drugs Industry Trends

2.3.2 Metabolic Disease Drugs Market Drivers

2.3.3 Metabolic Disease Drugs Market Challenges

2.3.4 Metabolic Disease Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Metabolic Disease Drugs by Players

3.1.1 Global Metabolic Disease Drugs Revenue by Players (2019-2024)

3.1.2 Global Metabolic Disease Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Metabolic Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Metabolic Disease Drugs, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Metabolic Disease Drugs Market Concentration Ratio

3.4.1 Global Metabolic Disease Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disease Drugs Revenue in 2023

3.5 Global Key Players of Metabolic Disease Drugs Head office and Area Served

3.6 Global Key Players of Metabolic Disease Drugs, Product and Application

3.7 Global Key Players of Metabolic Disease Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Metabolic Disease Drugs Breakdown Data by Type

4.1 Global Metabolic Disease Drugs Historic Market Size by Type (2019-2024)

4.2 Global Metabolic Disease Drugs Forecasted Market Size by Type (2025-2030)

5 Metabolic Disease Drugs Breakdown Data by Application

5.1 Global Metabolic Disease Drugs Historic Market Size by Application (2019-2024)

5.2 Global Metabolic Disease Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Metabolic Disease Drugs Market Size (2019-2030)

6.2 North America Metabolic Disease Drugs Market Size by Type

6.2.1 North America Metabolic Disease Drugs Market Size by Type (2019-2024)

6.2.2 North America Metabolic Disease Drugs Market Size by Type (2025-2030)

6.2.3 North America Metabolic Disease Drugs Market Share by Type (2019-2030)

6.3 North America Metabolic Disease Drugs Market Size by Application

6.3.1 North America Metabolic Disease Drugs Market Size by Application (2019-2024)

6.3.2 North America Metabolic Disease Drugs Market Size by Application (2025-2030)

6.3.3 North America Metabolic Disease Drugs Market Share by Application (2019-2030)

6.4 North America Metabolic Disease Drugs Market Size by Country

6.4.1 North America Metabolic Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Metabolic Disease Drugs Market Size by Country (2019-2024)

6.4.3 North America Metabolic Disease Drugs Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Metabolic Disease Drugs Market Size (2019-2030)

7.2 Europe Metabolic Disease Drugs Market Size by Type

7.2.1 Europe Metabolic Disease Drugs Market Size by Type (2019-2024)

7.2.2 Europe Metabolic Disease Drugs Market Size by Type (2025-2030)

7.2.3 Europe Metabolic Disease Drugs Market Share by Type (2019-2030)

7.3 Europe Metabolic Disease Drugs Market Size by Application

7.3.1 Europe Metabolic Disease Drugs Market Size by Application (2019-2024)

7.3.2 Europe Metabolic Disease Drugs Market Size by Application (2025-2030)

7.3.3 Europe Metabolic Disease Drugs Market Share by Application (2019-2030)

7.4 Europe Metabolic Disease Drugs Market Size by Country

7.4.1 Europe Metabolic Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Metabolic Disease Drugs Market Size by Country (2019-2024)

7.4.3 Europe Metabolic Disease Drugs Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Metabolic Disease Drugs Market Size (2019-2030)

8.2 China Metabolic Disease Drugs Market Size by Type

8.2.1 China Metabolic Disease Drugs Market Size by Type (2019-2024)

8.2.2 China Metabolic Disease Drugs Market Size by Type (2025-2030)

8.2.3 China Metabolic Disease Drugs Market Share by Type (2019-2030)

8.3 China Metabolic Disease Drugs Market Size by Application

8.3.1 China Metabolic Disease Drugs Market Size by Application (2019-2024)

8.3.2 China Metabolic Disease Drugs Market Size by Application (2025-2030)

8.3.3 China Metabolic Disease Drugs Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Metabolic Disease Drugs Market Size (2019-2030)

9.2 Asia Metabolic Disease Drugs Market Size by Type

9.2.1 Asia Metabolic Disease Drugs Market Size by Type (2019-2024)

9.2.2 Asia Metabolic Disease Drugs Market Size by Type (2025-2030)

9.2.3 Asia Metabolic Disease Drugs Market Share by Type (2019-2030)

9.3 Asia Metabolic Disease Drugs Market Size by Application

9.3.1 Asia Metabolic Disease Drugs Market Size by Application (2019-2024)

9.3.2 Asia Metabolic Disease Drugs Market Size by Application (2025-2030)

9.3.3 Asia Metabolic Disease Drugs Market Share by Application (2019-2030)

9.4 Asia Metabolic Disease Drugs Market Size by Region

9.4.1 Asia Metabolic Disease Drugs Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Metabolic Disease Drugs Market Size by Region (2019-2024)

9.4.3 Asia Metabolic Disease Drugs Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Type

10.2.1 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Application

10.3.1 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Country

10.4.1 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Merck

11.1.1 Merck Company Details

11.1.2 Merck Business Overview

11.1.3 Merck Metabolic Disease Drugs Introduction

11.1.4 Merck Revenue in Metabolic Disease Drugs Business (2019-2024)

11.1.5 Merck Recent Developments

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Metabolic Disease Drugs Introduction

11.2.4 Novartis Revenue in Metabolic Disease Drugs Business (2019-2024)

11.2.5 Novartis Recent Developments

11.3 Takeda Pharmaceutical

11.3.1 Takeda Pharmaceutical Company Details

11.3.2 Takeda Pharmaceutical Business Overview

11.3.3 Takeda Pharmaceutical Metabolic Disease Drugs Introduction

11.3.4 Takeda Pharmaceutical Revenue in Metabolic Disease Drugs Business (2019-2024)

11.3.5 Takeda Pharmaceutical Recent Developments

11.4 Astra Zeneca

11.4.1 Astra Zeneca Company Details

11.4.2 Astra Zeneca Business Overview

11.4.3 Astra Zeneca Metabolic Disease Drugs Introduction

11.4.4 Astra Zeneca Revenue in Metabolic Disease Drugs Business (2019-2024)

11.4.5 Astra Zeneca Recent Developments

11.5 Beohrigher Ingelheim

11.5.1 Beohrigher Ingelheim Company Details

11.5.2 Beohrigher Ingelheim Business Overview

11.5.3 Beohrigher Ingelheim Metabolic Disease Drugs Introduction

11.5.4 Beohrigher Ingelheim Revenue in Metabolic Disease Drugs Business (2019-2024)

11.5.5 Beohrigher Ingelheim Recent Developments

11.6 KOWA

11.6.1 KOWA Company Details

11.6.2 KOWA Business Overview

11.6.3 KOWA Metabolic Disease Drugs Introduction

11.6.4 KOWA Revenue in Metabolic Disease Drugs Business (2019-2024)

11.6.5 KOWA Recent Developments

11.7 Kythera

11.7.1 Kythera Company Details

11.7.2 Kythera Business Overview

11.7.3 Kythera Metabolic Disease Drugs Introduction

11.7.4 Kythera Revenue in Metabolic Disease Drugs Business (2019-2024)

11.7.5 Kythera Recent Developments

11.8 Fuji yakuhin

11.8.1 Fuji yakuhin Company Details

11.8.2 Fuji yakuhin Business Overview

11.8.3 Fuji yakuhin Metabolic Disease Drugs Introduction

11.8.4 Fuji yakuhin Revenue in Metabolic Disease Drugs Business (2019-2024)

11.8.5 Fuji yakuhin Recent Developments

11.9 LG Life Science

11.9.1 LG Life Science Company Details

11.9.2 LG Life Science Business Overview

11.9.3 LG Life Science Metabolic Disease Drugs Introduction

11.9.4 LG Life Science Revenue in Metabolic Disease Drugs Business (2019-2024)

11.9.5 LG Life Science Recent Developments

11.10 Metsubishi Tanabe Pharma

11.10.1 Metsubishi Tanabe Pharma Company Details

11.10.2 Metsubishi Tanabe Pharma Business Overview

11.10.3 Metsubishi Tanabe Pharma Metabolic Disease Drugs Introduction

11.10.4 Metsubishi Tanabe Pharma Revenue in Metabolic Disease Drugs Business (2019-2024)

11.10.5 Metsubishi Tanabe Pharma Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Metabolic Disease Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Glycogen Metabolism Disease Drug

Table 3. Key Players of Lipid Metabolism Disease Drug

Table 4. Key Players of Amino Acid Metabolism Drug

Table 5. Key Players of Other

Table 6. Global Metabolic Disease Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 7. Global Metabolic Disease Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Metabolic Disease Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Metabolic Disease Drugs Market Share by Region (2019-2024)

Table 10. Global Metabolic Disease Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Metabolic Disease Drugs Market Share by Region (2025-2030)

Table 12. Metabolic Disease Drugs Market Trends

Table 13. Metabolic Disease Drugs Market Drivers

Table 14. Metabolic Disease Drugs Market Challenges

Table 15. Metabolic Disease Drugs Market Restraints

Table 16. Global Metabolic Disease Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Metabolic Disease Drugs Revenue Share by Players (2019-2024)

Table 18. Global Top Metabolic Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2023)

Table 19. Global Metabolic Disease Drugs Industry Ranking 2022 VS 2023 VS 2024

Table 20. Global 5 Largest Players Market Share by Metabolic Disease Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 21. Global Key Players of Metabolic Disease Drugs, Headquarters and Area Served

Table 22. Global Key Players of Metabolic Disease Drugs, Product and Application

Table 23. Global Key Players of Metabolic Disease Drugs, Product and Application

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Metabolic Disease Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Metabolic Disease Drugs Revenue Market Share by Type (2019-2024)

Table 27. Global Metabolic Disease Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Metabolic Disease Drugs Revenue Market Share by Type (2025-2030)

Table 29. Global Metabolic Disease Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Metabolic Disease Drugs Revenue Share by Application (2019-2024)

Table 31. Global Metabolic Disease Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Metabolic Disease Drugs Revenue Share by Application (2025-2030)

Table 33. North America Metabolic Disease Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 34. North America Metabolic Disease Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 35. North America Metabolic Disease Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 36. North America Metabolic Disease Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 37. North America Metabolic Disease Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. North America Metabolic Disease Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 39. North America Metabolic Disease Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 40. Europe Metabolic Disease Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 41. Europe Metabolic Disease Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 42. Europe Metabolic Disease Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 43. Europe Metabolic Disease Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 44. Europe Metabolic Disease Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Europe Metabolic Disease Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 46. Europe Metabolic Disease Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 47. China Metabolic Disease Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 48. China Metabolic Disease Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 49. China Metabolic Disease Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 50. China Metabolic Disease Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 51. Asia Metabolic Disease Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 52. Asia Metabolic Disease Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 53. Asia Metabolic Disease Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 54. Asia Metabolic Disease Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 55. Asia Metabolic Disease Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 56. Asia Metabolic Disease Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 57. Asia Metabolic Disease Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Type (2025-2030) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Application (2025-2030) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Metabolic Disease Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 63. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 64. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 65. Merck Company Details

Table 66. Merck Business Overview

Table 67. Merck Metabolic Disease Drugs Product

Table 68. Merck Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 69. Merck Recent Developments

Table 70. Novartis Company Details

Table 71. Novartis Business Overview

Table 72. Novartis Metabolic Disease Drugs Product

Table 73. Novartis Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 74. Novartis Recent Developments

Table 75. Takeda Pharmaceutical Company Details

Table 76. Takeda Pharmaceutical Business Overview

Table 77. Takeda Pharmaceutical Metabolic Disease Drugs Product

Table 78. Takeda Pharmaceutical Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 79. Takeda Pharmaceutical Recent Developments

Table 80. Astra Zeneca Company Details

Table 81. Astra Zeneca Business Overview

Table 82. Astra Zeneca Metabolic Disease Drugs Product

Table 83. Astra Zeneca Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 84. Astra Zeneca Recent Developments

Table 85. Beohrigher Ingelheim Company Details

Table 86. Beohrigher Ingelheim Business Overview

Table 87. Beohrigher Ingelheim Metabolic Disease Drugs Product

Table 88. Beohrigher Ingelheim Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 89. Beohrigher Ingelheim Recent Developments

Table 90. KOWA Company Details

Table 91. KOWA Business Overview

Table 92. KOWA Metabolic Disease Drugs Product

Table 93. KOWA Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 94. KOWA Recent Developments

Table 95. Kythera Company Details

Table 96. Kythera Business Overview

Table 97. Kythera Metabolic Disease Drugs Product

Table 98. Kythera Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 99. Kythera Recent Developments

Table 100. Fuji yakuhin Company Details

Table 101. Fuji yakuhin Business Overview

Table 102. Fuji yakuhin Metabolic Disease Drugs Product

Table 103. Fuji yakuhin Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 104. Fuji yakuhin Recent Developments

Table 105. LG Life Science Company Details

Table 106. LG Life Science Business Overview

Table 107. LG Life Science Metabolic Disease Drugs Product

Table 108. LG Life Science Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 109. LG Life Science Recent Developments

Table 110. Metsubishi Tanabe Pharma Company Details

Table 111. Metsubishi Tanabe Pharma Business Overview

Table 112. Metsubishi Tanabe Pharma Metabolic Disease Drugs Product

Table 113. Metsubishi Tanabe Pharma Revenue in Metabolic Disease Drugs Business (2019-2024) & (US$ Million)

Table 114. Metsubishi Tanabe Pharma Recent Developments

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Metabolic Disease Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Metabolic Disease Drugs Market Share by Type: 2023 VS 2030

Figure 3. Glycogen Metabolism Disease Drug Features

Figure 4. Lipid Metabolism Disease Drug Features

Figure 5. Amino Acid Metabolism Drug Features

Figure 6. Other Features

Figure 7. Global Metabolic Disease Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 8. Global Metabolic Disease Drugs Market Share by Application: 2023 VS 2030

Figure 9. Hospital Pharmacy Case Studies

Figure 10. Retail Pharmacy Case Studies

Figure 11. Metabolic Disease Drugs Report Years Considered

Figure 12. Global Metabolic Disease Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Metabolic Disease Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Metabolic Disease Drugs Market Share by Region: 2023 VS 2030

Figure 15. Global Metabolic Disease Drugs Market Share by Players in 2023

Figure 16. Global Top Metabolic Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Metabolic Disease Drugs Revenue in 2023

Figure 18. North America Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Metabolic Disease Drugs Market Share by Type (2019-2030)

Figure 20. North America Metabolic Disease Drugs Market Share by Application (2019-2030)

Figure 21. North America Metabolic Disease Drugs Market Share by Country (2019-2030)

Figure 22. United States Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Metabolic Disease Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 25. Europe Metabolic Disease Drugs Market Share by Type (2019-2030)

Figure 26. Europe Metabolic Disease Drugs Market Share by Application (2019-2030)

Figure 27. Europe Metabolic Disease Drugs Market Share by Country (2019-2030)

Figure 28. Germany Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. China Metabolic Disease Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 35. China Metabolic Disease Drugs Market Share by Type (2019-2030)

Figure 36. China Metabolic Disease Drugs Market Share by Application (2019-2030)

Figure 37. Asia Metabolic Disease Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 38. Asia Metabolic Disease Drugs Market Share by Type (2019-2030)

Figure 39. Asia Metabolic Disease Drugs Market Share by Application (2019-2030)

Figure 40. Asia Metabolic Disease Drugs Market Share by Region (2019-2030)

Figure 41. Japan Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. South Korea Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. China Taiwan Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. India Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Australia Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Size YoY (2019-2030) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Share by Type (2019-2030)

Figure 49. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Share by Application (2019-2030)

Figure 50. Middle East, Africa, and Latin America Metabolic Disease Drugs Market Share by Country (2019-2030)

Figure 51. Brazil Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 52. Mexico Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Turkey Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Israel Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. GCC Countries Metabolic Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. Merck Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 58. Novartis Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 59. Takeda Pharmaceutical Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 60. Astra Zeneca Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 61. Beohrigher Ingelheim Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 62. KOWA Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 63. Kythera Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 64. Fuji yakuhin Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 65. LG Life Science Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 66. Metsubishi Tanabe Pharma Revenue Growth Rate in Metabolic Disease Drugs Business (2019-2024)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Metabolic Disease Drugs in 2024? zhanKai

The global market size of Metabolic Disease Drugs in 2024 was 90370 Million USD.

Which companies rank high in the global Metabolic Disease Drugs market? shouQi

What was the global market size of Metabolic Disease Drugs in 2030? shouQi

Which region is expected to have the highest market share? shouQi

What is the annual compound growth rate of the global Metabolic Disease Drugs market size from 2024 to 2030? shouQi

Related Reports

Global Metabolic Disease Drugs Market Research Report 2025
The global market for Metabolic Disease Drugs was valued at US$ 90370 million in the year 2024 and is projected to reach a revised size of US$ 175600 million by 2031, growing at a CAGR of 10.1% during the forecast period.
Published Date: 2025-01-01
Pages: 75
USD 2900.00
(Single User License)
Global Metabolic Disease Drugs Market Research Report 2024
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published Date: 2024-01-12
Pages: 89
USD 2900.00
(Single User License)
Metabolic Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published Date: 2024-01-08
Pages: 109
USD 3950.00
(Single User License)

Global Metabolic Disease Drugs Market Research Report 2025
The global market for Metabolic Disease Drugs was valued at US$ 90370 million in the year 2024 and is projected to reach a revised size of US$ 175600 million by 2031, growing at a CAGR of 10.1% during the forecast period.
Published: 2025-01-01
Pages: 75
USD 2900.00 (Single User License)
Global Metabolic Disease Drugs Market Research Report 2024
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published: 2024-01-12
Pages: 89
USD 2900.00 (Single User License)
Metabolic Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published: 2024-01-08
Pages: 109
USD 3950.00 (Single User License)